TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Participants must:~* Have been diagnosed with type 2 diabetes mellitus (T2DM)~* Have HbA1c between ≥7.5% and ≤10.5%~* Be on stable treatment with unchanged dose of at least 1 and no more than 3 types of oral antihyperglycemic drugs, which may only include metformin, SGLT-2 inhibitors, and/or sulfonylureas for at least 3 months before screening~* Have increased risk for cardiovascular (CV) events~* Be of stable weight (± 5%)~* Have a BMI ≥25 kilograms per meter squared (kg/m2) at screening~Exclusion Criteria~Participants must not:~* Have type 1 diabetes mellitus~* Have had chronic or acute pancreatitis any time prior to study entry~* Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring immediate or urgent treatment~* Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss~* Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) enzyme level \>3.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory. Participants with nonalcoholic fatty liver disease (NAFLD) are eligible for participation in this trial only if there ALT level is ≤3.0 the ULN for the reference range~* Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months~* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2~* Have been taking any other diabetes medicines other than metformin, SGLT-2 inhibitors, and/or sulfonylureas during the last 3 months~* Have been taking weight loss drugs, including over-the-counter medications during the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
- 10 mg Tirzepatide (Type: EXPERIMENTAL): 10 mg tirzepatide administered SC once a week.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): 15 mg tirzepatide administered SC once a week.
- Insulin Glargine (Type: ACTIVE_COMPARATOR): Insulin glargine administered SC once a day. Doses were individualized and titrated according to protocol-defined targets.~The starting dose of insulin glargine was 10 IU/day at bedtime, titrated to a FBG \<100 mg/dL, following a treat-to-target (TTT) algorithm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For GPP~* Have a diagnosis of GPP for at least 60 days prior to informed consent based on the diagnostic criteria of the Japanese Dermatological Association (JDA). Subjects not fulfilling one of the diagnostic criteria i.e., accompanying systemic symptoms including fever or malaise at the time of screening can be entered.~* Subjects with an erythema area with pustules accounting for ≥ 10% of the body surface area (BSA), and with a severity assessment criteria score (JDA total score) specified by the JDA of less than 14.~* Must be candidates for systemic therapy or phototherapy for GPP, as assessed by the investigator.~For EP~* Have a diagnosis of EP prior to informed consent.~* Subjects with an inflammatory erythema area accounting for ≥ 80% of the BSA at screening and at the time of the first administration of the study drug.~* Must be candidates for systemic therapy or phototherapy for EP, as assessed by the investigator.~Exclusion Criteria:~* Previous exposure to risankizumab.~* Currently enrolled in another investigational study or less than 30 days (from screening) since completing another investigational study (participation in observational studies is permitted).~For GPP~* Subjects with active ongoing inflammatory diseases other than GPP that might confound trial evaluations according to investigator's judgment.~For EP~* Subjects with active ongoing inflammatory diseases other than EP that might confound trial evaluations according to investigator's judgment.~* Subject diagnosed with medication-induced or medication-exacerbated EP.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Risankizumab 75 mg (Type: EXPERIMENTAL): Participants randomized to receive risankizumab 75 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
- Risankizumab 150 mg (Type: EXPERIMENTAL): Participants randomized to receive risankizumab 150 mg at Week 0, Week 4, and every 12 weeks up to Week 172.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lung Transplant READY Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cystic fibrosis~* FEV1 less than or equal to 50% predicted (unless referred per MD recommendation)~Exclusion Criteria:~* Patients unable to provide informed consent~* Patients who are lung transplant recipients~* Unable to read or understand English to complete surveys or access the websites (currently only available in English)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Access to an investigator-designed web-based educational resource with information about lung transplant for two weeks.
- Control (Type: ACTIVE_COMPARATOR): Access to a publicly available web-based educational resource with information about transplant for two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D for Chemoprevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 30 and 80 years~* Comfortable communicating in English~* Currently has a primary care physician~* Willing to discontinue vitamin D or calcium supplements~* Willing to have all protocol specific tests run~Exclusion Criteria:~* Plans on taking a vacation or travel to a sunny region within 3 months of vitamin supplementation period except for a short period (i.e. 1 weekend)~* Pregnant or breast feeding or planning on becoming pregnant in the following year~* Pre-existing calcium (including hypercalcemia), parathyroid conditions (including hyperparathyroidism), sarcoidosis~* No concurrent active malignancies (other than non-melanoma skin cancer) or previous diagnosis of prostate cancer~* Cognitively impaired~* Active thyroid disease (e.g. Graves, Hashimoto's or thyroiditis)~* History of nephrolithiasis, chronic liver disease, chronic renal disease, or renal dialysis

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): No Vitamin D
- 2 (Type: ACTIVE_COMPARATOR): 1000 IU of Vitamin D
- 3 (Type: ACTIVE_COMPARATOR): 2000 IU of Vitamin D
- 4 (Type: ACTIVE_COMPARATOR): 4000 IU of Vitamin D

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with solid tumour(s)~* Anaemia (hgb less than or equal to 11.0 g/dL~* Planned to receive cyclic chemotherapy~* At least 6-month life expectancy~* Eastern Cooperative Oncology Group (ECOG) status of 0 to 2~* Adequate renal and liver function~* At least 18 years of age~Exclusion Criteria:~* Central nervous system disease~* Iron deficiency~* Received more than 2 RBC transfusions within 4 weeks before randomisation or any RBC transfusion within 2 weeks before randomisation~* Received recombinant human erythropoietin (rHuEPO) therapy within 8 weeks before randomisation~* History of any seizure disorder~* Cardiac disease~* Active infection or inflammatory disease~* Known positive test for HIV infection~* Known primary haematologic disorder which could cause anaemia~* Use of other investigational agent(s)/device(s)~* Pregnant or breast feeding~* Known hypersensitivity to any recombinant mammalian derived product

- Gender: None
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NESP - Schedule 1 Part A (Type: EXPERIMENTAL): Part A - 4.5, 6.75, 9.0 or 13.5 mcg/kg Q3W for 12 weeks
- NESP - Schedule 2 Part A (Type: EXPERIMENTAL): NESP 9.0, 12.0, 15.0 or 18.0 mcg/kg Q4W for 12 weeks
- Placebo - Schedule 1 Part A (Type: PLACEBO_COMPARATOR): Placebo Q3W for 12 weeks
- NESP - Schedule 1 Part B (Type: EXPERIMENTAL): Open-label NESP at the dose of study drug administered at the end of Part A. Increase dose at week 19 if hgb \< 13.0g/dL and/or RBC transfusion in previous 2 weeks.
- Placebo - Schedule 2 Part A (Type: PLACEBO_COMPARATOR): Placebo Q4W for 12 weeks
- NESP - Schedule 2 Part B (Type: EXPERIMENTAL): Open-label NESP at the dose of study drug administered at the end of Part A

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate essential hypertension : sitting diastolic blood pressure measured at Placebo visit and Baseline are 90\~109mmHg inclusive and the difference between sitting diastolic blood pressures measured at Placebo visit and Baseline(Day0) is under 7mmHg.~* Subjects who agree to participate in this sudy and give written informed consent~* Subjects considered to understand the study, be cooperative, and able to be followed-up until the end of the study~Exclusion Criteria:~* The sitting DBP is less than 89mmHg or more than 110mmHg or severe hypertensive patient with sitting systolic blood pressure over 200mmHg Patients with secondary hypertension~* Patients with severe renal(Creatinine more 1.5mg/dl), gastrointestinal, hematological or hepatic(AST, ALT more 2 twice more than upper limit of normal)disease etc. which might affect absorption, disposition, metabolism or excretion of the drug~* Patients with postural hypotension~* Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes mellitus(HbA1c\>9%, regimen change of oral hypoglycemic agents within 12weeks, treated insulin before screening)~* Patients with a history of myocardial infarction, severe coronary artery disease or clinically significant heart failure or valvular defect in last 6 months~* Patients with consumptive disease, autoimmune disease, connective tissue disease~* Patients with a history of type B or C hepatitis~* Patients with HIV or hepatitis~* Patients with clinically significant laboratory abnormality~* Patients receiving any drugs known to affect blood pressure or medical treatments that can influence the blood pressure~* Patients with allergy or contraindication to any angiotensin II receptor antagonists~* Female of childbearing potential who does not undergo hysterectomy or is not post-menopausal~* Patients judged to have a history of alcohol or drug abuse by the investigator~* Patients participated other clinical trial 12 weeks before Screening Patients judged to be inappropriate for this study by the investigator with other reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fimasartan 1 (Type: EXPERIMENTAL): Fimasartan 60 mg group
- Fimasartan 2 (Type: EXPERIMENTAL): Fimasartan 120 mg group
- Valsartan (Type: ACTIVE_COMPARATOR): Reference (Valsartan 80 mg) group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight/obese adult males/females 18-75 years of age with a BMI ≥ 27 kg/m2;~* At least 1 weight-related comorbidity (i.e., hypertension, dyslipidemia, Type 2 diabetes mellitus \[T2DM\] or prediabetes, or obstructive sleep apnea).~* Must be ambulatory, willing, and able to wear ABPM monitor apparatus for 24 hours at beginning and end of study.~Exclusion Criteria:~* Screening blood pressure of \> 140/90 mmHg;~* Type 1 diabetes; T2DM treated with SFUs, GLP-1 receptor agonists, SGLT inhibitors; or not on stable diabetic medications for at least 3 months prior to randomization;~* Clinically significant cardiac, hepatic, renal, pulmonary, or thyroid disease;~* History of bipolar disorder, psychosis, greater than one lifetime episode of major depressive disorder, or presence or history of suicidal behavior or suicidal ideation with intent to act;~* History of glaucoma;~* Night shift workers;~* Obesity of known genetic or endocrine origin; recent history of weight instability, or recent participation in a formal weight loss program within 3 months prior to screening; and~* Smoking cessation within 3 months prior to screening;~* Use of antihypertensive medications, antidiabetic medications, statins or other lipid lowering agents, or CPAP therapy that has not been stable for at least 3 months prior to randomization;~* COVID-19 vaccination or treatment for severe COVID-19 infection within a month prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg) (Type: EXPERIMENTAL): Week 1: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Week 2: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily; Week 3: VI-0521 (Phentermine 11.25 mg + Topiramate 69 mg) oral capsule, once daily; Weeks 4-8: VI-0521 (Phentermine 15 mg + Topiramate 92 mg) oral capsule, once daily
- Phentermine 30mg (Type: ACTIVE_COMPARATOR): Weeks 1-8: Phentermine 30mg oral capsule, once daily
- Placebo (Type: PLACEBO_COMPARATOR): Weeks 1-8: Placebo oral capsule, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapy to Elevate CD4 Counts in HIV-1 Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 patients must have confirmed HIV-1 disease, diagnosed using the standard criteria and be on antiretroviral therapy. Patients with inherited alpha-1 proteinase inhibitor deficiency (PIzz) must not have previously received alpha-1 proteinase inhibitor therapy. Uninfected volunteers will be age and gender matched.~2. HIV-1 patients must have measurable disease, defined as HIV-1 infected patients on antiretroviral therapy with undetectable HIV RNA (\<500 HIV-1 RNA copies/ml) and CD4 counts more than 200 and less than 400 cells/uL.~3. Age at least 18 years and under 65 years.~4. HIV-1 patients must have active alpha-1 proteinase inhibitor below 11uM (normal is 18-53 uM).~5. HIV-1 patients must have one year history (prior to the study) with CD4 counts greater than 200 and less than 400 cells/uL.~6. Volunteers must have no evidence of malignancy.~Exclusion Criteria:~1. Recent illness that will prevent the patient from participating in required study activities.~2. Patients receiving other investigational agents.~3. Patients with known malignancies.~4. Patients with more than 500 HIV RNA copies/mL.~5. Patients with more than 400 CD4 cells/uL.~6. Uncontrolled illness including, but not limited to, ongoing or active infection, myeloid dysplastic syndrome, anemia, bone marrow failure, DiGeorge Syndrome, thymic disorders, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- alpha-1 proteinase inhibitor in HIV (Type: EXPERIMENTAL): HIV-1 infected individuals treated with Alpha-1 proteinase inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult overactive bladder (OAB) patients who present with OAB symptoms, including urinary frequency \>= 8 per day and urgency urinary incontinence \>=1 per day~Exclusion Criteria:~* Patients with conditions that would contraindicate for fesoterodine use, e.g, hypersensitivity to the active substance (fesoterodine) or to peanut or soya or any of the excipients, urinary retention, and gastric retention.~* Patients with significant hepatic and renal disease or other significant unstable diseases.~* OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fesoterodine (Type: EXPERIMENTAL): Tablets
- Placebo (Type: PLACEBO_COMPARATOR): Tablets and capsules
- Tolterodine (Type: ACTIVE_COMPARATOR): Capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent~* Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at screening with at least 1 fibroid with largest diameter 3.0 cm~* 18 to 50 years of age at the time of screening~* Heavy menstrual bleeding \>80 mL documented by MP during the bleeding episode following the screening visit~* Normal or clinically insignificant cervical smear not requiring further follow-up~* An endometrial biopsy performed at the screening visit 1 (Visit 1), without significant histological disorder such as endometrial hyperplasia or other significant endometrial pathology~* Use of a non-hormonal barrier method of contraception starting at the bleeding episode following the screening visit 1 (Visit 1) until the end of the study~* Good general health (except for findings related to uterine fibroids)~Exclusion Criteria:~* Pregnancy or lactation~* Uterine fibroid with largest diameter \>10.0 cm~* Hypersensitivity to any ingredient of the study drug~* Laboratory values outside inclusion range before randomization and considered as clinically relevant~* Hemoglobin values \<6 g/dL or any condition requiring immediate blood transfusion (subjects with hemoglobin values \<10.9 g/dL will receive iron supplementation)~* Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- VPR 4 mg (Type: EXPERIMENTAL): None
- VPR 2 mg (Type: EXPERIMENTAL): None
- VPR 1 mg (Type: EXPERIMENTAL): None
- VPR 0.5 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Local Anesthetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient scheduled to undergo comprehensive dental treatment under general anesthesia at the Koppel Special Care Dentistry Center at Loma Linda University School of Dentistry~* ASA I or II health status~* Age greater than 3 years but less than 6 years~* Weigh between 10kg and 25kg~Exclusion Criteria:~* Patient not requiring restorative dental treatment~* Have a BMI less than the 5th percentile or greater than the 95th percentile for their age and gender

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Prilocaine (Type: EXPERIMENTAL): 30 subjects will receive 5mg/kg of 4% prilocaine plain local anesthetic for restorative dental treatment under general anesthesia
- Lidocaine (Type: EXPERIMENTAL): 30 subjects will receive 2.5mg/kg of 2% lidocaine with 1:100,000 epinephrine local anesthetic for restorative dental treatment under general anesthesia
- No local anesthetic (Type: NO_INTERVENTION): 30 subjects will not receive local anesthetic for dental treatment under general anesthesia-Negative control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete